Emergent BioSolutions | EBS - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
Acadia Pharmaceuticals USD 257.76M 778K 2025-12
Akebia Therapeutics USD 47.28M 1.7M 2025-12
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 23.17M 961K 2025-12
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
BioMarin Pharmaceutical USD 713.01M 81.81M 2025-12
Coherus Biosciences USD 8.7M 853K 2025-12
Exelixis USD 572.18M 7M 2025-12
Glaxosmithkline GBP 8.75B 2.92B 2025-09
Heron Therapeutics USD 29.47M 3.17M 2025-12
Ionis Pharmaceuticals USD 195M 40M 2025-12
Ironwood Pharmaceuticals USD 85.24M 44.1M 2025-06
Lexicon Pharmaceuticals USD 5.29M 8.88M 2025-12
Lonza CHF 1.29B 248M 2025-06
Merck USD 13.42B 431M 2025-09
Moderna USD 226M 583M 2025-12
Myriad Genetics USD 146.8M 3M 2025-12
Nektar Therapeutics USD 13.75M 650K 2024-06
Neurocrine Biosciences USD 787.9M 7M 2025-12
Pacira USD 142.25M 11.34M 2025-12
Pfizer USD 3.54B 7.61B 2025-09
PTC Therapeutics USD 148.38M 39.31M 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Sarepta Therapeutics USD 43.55M 204.36M 2025-12
United Therapeutics USD 315.5M 286.6M 2025-12
Vanda Pharmaceuticals USD 50.6M 5.5M 2024-12
Xoma 992K 846K 2024-06